SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
STRO reported Third quarter ended September 30, 2026 results. The price and volatility reaction is pending.
STROearnings

Earnings reactions, page 3

Sutro Biopharma, Inc. (STRO) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue was $9.1 million for the quarter ended September 30, 2026.
  • Total operating expenses were $31.1 million for the quarter ended September 30, 2026.
  • Net loss was $31.5 million for the quarter ended September 30, 2026.
  • Net loss per share, basic and diluted, was $1.90 for the quarter ended September 30, 2026.
  • Cash, cash equivalents and marketable securities were $142.2 million as of September 30, 2026.

Guidance

  • The Company expects its cash runway to support operations into the first half of 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →